Histone deacetylases and their inhibitors as potential therapeutic drugs for cholangiocarcinoma -cell line findings

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 4, 2013, Pages 2503-2508

  Sriraks, Ruethairat ^a   Limpaiboon, Temduang ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Cell lines; Cholangiocarcinoma; Epigenetics; Histone deacetylase; Inhibitor

Indexed keywords

EID: 84880322892     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.4.2503     Document Type: Article

References (36)

1. Balasubramanian S, Verner E,Buggy JJ (2009). Isoform-specific histone deacetylase inhibitors: the next step? Cancer Lett, 280, 211-21.
2. Blaheta RA, Cinatl J, Jr. (2002). Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev, 22, 492-511.
3. Butler LM, Zhou X, Xu WS, et al (2002). The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci USA, 99, 11700-5.
4. Chen MY, Liao WS, Lu Z, et al (2011). Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy Cancer, 117, 4424-38.
5. Cinatl J, Jr., Cinatl J, Driever PH, et al (1997). Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anticancer Drugs, 8, 958-63.
6. Fritsche P, Seidler B, Schuler S, et al (2009). HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. Gut, 58, 1399-409.
7. Hejna M, Pruckmayer M, Raderer M (1998). The role of chemotherapy and radiation in the management of biliary cancer: a review of the literature. Eur J Cancer, 34, 977-86.
8. Iwahashi S, Ishibashi H, Utsunomiya T, et al (2011). Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer andcholangiocarcinoma cell lines. J Med Invest, 58, 106-9.
9. Kelly WK, Marks PA (2005). Drug insight: Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol, 2,150-7.
10. Khan SA, Davidson BR, Goldin R, et al (2002). Guidelines for the diagnosis and treatment of cholangiocarcinoma:consensus document. Gut, 51, 7-9.
11. Kumagai T, Wakimoto N, Yin D, et al (2007). Histone deacetylase inhibitor, suberoylanilide hydroxamic acid(Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells. Int J Cancer, 121, 656-65.
12. Lee MA, Woo IS, Kang JH, et al (2004). Epirubicin, cisplatin,and protractedinfusion of 5-FU (ECF) in advanced intrahepatic cholangiocarcinoma. J Cancer Res Clin Oncol,130, 346-50.
13. Limpaiboon T (2012). Epigenetic aberrations in cholangiocarcinoma: potential biomarkers and promising target for novel therapeutic strategies. Asian Pac J Cancer Prev, 13, 41-5.
14. Lin RJ, Nagy L, Inoue S, et al (1998). Role of the histone deacetylase complex in acute promyelocytic leukaemia.Nature, 391, 811-4.
15. Marks PA, Dokmanovic M (2005). Histone deacetylase inhibitors: discovery and development as anticancer agents.Expert Opin Investig Drugs, 14, 1497-511.
16. Martin R, Jarnagin W (2003). Intrahepatic cholangiocarcinoma.Current management. Minerva Chir, 58, 469-78.
17. Morine Y, Shimada M, Iwahashi S, et al (2012). Role of histone deacetylase expression in intrahepatic cholangiocarcinoma.Surgery, 151, 412-9.
18. Mutze K, Langer R, Becker K, et al (2010). Histone deacetylase(HDAC) 1 and 2 expression and chemotherapy in gastric cancer. Ann Surg Oncol, 17, 3336-43.
19. Pan LN, Lu J, Huang B (2007). HDAC inhibitors: a potential new category of anti-tumor agents.Cell Mol Immunol, 4, 337-43.
20. Patel T (2006). Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol, 3, 33-42.
21. Patra SK, Patra A, Dahiya R (2001). Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun, 287, 705-13.
22. Patt YZ, Hassan MM, Lozano RD, et al (2001). Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer. Clin Cancer Res, 7, 3375-80.
23. Rikiishi H (2011). Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol, 2011,830260.
24. Shao Y, Gao Z, Marks PA, et al (2004). Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc NatlAcadSci USA, 101, 18030-5.
25. Sharma S, Kelly TK, Jones PA (2010). Epigenetics in cancer.Carcinogenesis, 31, 27-36.
26. Shukla V, Vaissiere T, Herceg Z (2008). Histone acetylation and chromatin signature in stem cell identity and cancer. Mutat Res, 637, 1-15.
27. Sia D, Tovar V, Moeini A, et al (2013). Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies. Oncogene, doi: 10.1038/onc.2012.617.
28. Stiborova M, Eckschlager T, Poljakova J, et al (2012). The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment. Curr Med Chem, 19, 4218-38.
29. Thongprasert S (2005). The role of chemotherapy in cholangiocarcinoma. ann Oncol, 16, 93-6.
30. Venkataramani V, Rossner C, Iffland L, et al (2010). Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. JBiol Chem, 285, 10678-89.
31. Vichai V, Kirtikara K (2006). Sulforhodamine B colorimetric assay for cytotoxicity screening. NatProtoc, 1, 1112-6.
32. Vigushin DM, Coombes RC (2002). Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs, 13, 1-13.
33. Weichert W, Roske A, Gekeler V, et al (2008). Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer, 98, 604-10.
34. Xia Q, Sung J, Chowdhury W, et al (2006). Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo. Cancer Res, 66, 7237-44.
35. Yamaguchi J, Sasaki M, Sato Y, et al (2010). Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma. Cancer Sci, 101, 355-62.
36. Zabron A, Edwards RJ, Khan SA (2013). The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer. Dis model mech 6, 281-92.